TRPX - Therapix Biosciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Therapix Biosciences Ltd.

Hashahar Tower
16th Floor 4 Ariel Sharon Street
Givatayim 5320047
Israel
972 3 616 7055
http://therapixbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Dr. Ascher ShmulewitzChairman & CEO401kN/A1956
Mr. Oz Adler CPAChief Financial Officer209kN/A1987
Dr. Adi Zuloff-ShaniChief Technology Officer258kN/A1968
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.

Corporate Governance

Therapix Biosciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.